Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation

被引：0
|
作者：
Massarweh, S
Osborne, CK
Wakeling, AE
Schiff, R
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Astra Zeneca, Macclesfield, Cheshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [1] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [2] Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database.
    Nahleh, Zeina A.
    Hobbs, Brian
    Elimimian, Elizabeth
    Wei, Wei
    Gupta, Annie
    Blake, Cassann N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] CYP2D6 genotype predicts tamoxifen side effects but not cancer-free or survival benefits in postmenopausal ER+ and/or PgR+ breast cancers
    不详
    PHARMACOGENOMICS, 2013, 14 (05) : 462 - 463
  • [4] Estrogen receptor positive (ER+), progesterone receptor negative (PgR-) breast cancer: new insights into molecular mechanisms and clinical implications
    Arpino, G
    Weiss, H
    Lee, A
    Schiff, R
    Osborne, CK
    Elledge, RM
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S21 - S21
  • [5] Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+Breast Cancer
    Menendez, Javier A.
    Papadimitropoulou, Adriana
    Vander Steen, Travis
    Cuyas, Elisabet
    Oza-Gajera, Bharvi P.
    Verdura, Sara
    Espinoza, Ingrid
    Vellon, Luciano
    Mehmi, Inderjit
    Lupu, Ruth
    CANCERS, 2021, 13 (05) : 1 - 19
  • [6] Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
    Jin Zhang
    Qianying Wang
    Qing Wang
    Jiangran Cao
    Jiafu Sun
    Zhengmao Zhu
    Cellular and Molecular Life Sciences, 2020, 77 : 559 - 572
  • [7] Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer
    Goetz, M. P.
    Reinicke, K. E.
    Reid, J. M.
    Suman, V. J.
    Kuffel, M. J.
    Safgren, S. L.
    Buhrow, S. A.
    Reynolds, C. A.
    Jenkins, R. B.
    Hawse, J. R.
    Perez, E. A.
    Ingle, J. N.
    Ames, M. M.
    CANCER RESEARCH, 2009, 69 (24) : 594S - 594S
  • [8] IBCSG -: International Breast Cancer Study Group IBCSG trial 11-93 design:: N+, ER+ or PgR+, premenopausal breast cancer
    Thürlimann, B
    ONKOLOGIE, 1998, 21 (03): : 266 - 267
  • [9] Analysis of 47 Patients with Triple Negative (ER, PGR, HER2) Breast Cancer
    Gunes, Mehmet Emin
    Celik, Gurhan
    Trabulus, Fadime Didem
    Aksoy, Sefika
    Ozoran, Emre
    Aren, Acar
    Gucin, Zuhal
    Bahadir, Fadime
    ISTANBUL MEDICAL JOURNAL, 2012, 13 (04): : 166 - 168
  • [10] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
    C. Criscitiello
    A. Vingiani
    P. Maisonneuve
    G. Viale
    G. Viale
    G. Curigliano
    Breast Cancer Research and Treatment, 2020, 183 : 347 - 354
12345